GRI Bio
6 hedge funds and large institutions have $49.7K invested in GRI Bio in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more funds holding
Funds holding: 4 → 6 (+2)
0.02% less ownership
Funds ownership: 0.03% → 0.01% (-0.02%)
64% less capital invested
Capital invested by funds: $140K → $49.7K (-$90K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$45.5K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$27.4K |
| 3 |
HF
HRT Financial
New York
|
+$11.7K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$10.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$96.4K |
| 2 |
BlackRock
New York
|
-$402 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $25.9K | +$45.5K | +113 | +297% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $11.7K | +$27.4K | +68 | New |
|
|
HF
3
HRT Financial
New York
| $5K | +$11.7K | +29 | New |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $4.28K | +$10.1K | +25 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $1.61K | +$3.22K | +8 | +800% |
|
|
6
BlackRock
New York
| $1.3K | -$402 | -1 | -11% |
|
7
Bank of America
Charlotte,
North Carolina
| $8 | – | – | – |
|
|
AC
8
Armistice Capital
New York
| – | -$96.4K | -105 | Closed |
|
GRI Hedge Fund Activity: Q3 2024 in Review
6 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in GRI Bio (GRI) for Q3 2024, worth a combined $49.7K — down 64% from $140K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new GRI positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $45.5K. The largest seller was Armistice Capital, exiting entirely with an estimated $96.4K sold.
- 6 institutional investors held GRI Bio (GRI) as of Q3 2024, up from 4 in Q2 2024.
- Funds reported $49.7K of GRI Bio stock for Q3 2024, down 64% quarter-over-quarter.
- 3 funds opened new GRI Bio positions in Q3 2024 and 1 closed out, a net change of +2 holders.
- The largest GRI Bio buyer in Q3 2024 was UBS Group, an estimated $45.5K added.
- The largest GRI Bio seller in Q3 2024 was Armistice Capital, an estimated $96.4K sold.
Based on aggregated 13F filings for Q3 2024.